{"id":"https://openalex.org/W3133664844","doi":"https://doi.org/10.1002/prp2.740","title":"Optimization of dose and route of administration of the P\u2010glycoprotein inhibitor, valspodar (PSC\u2010833) and the P\u2010glycoprotein and breast cancer resistance protein dual\u2010inhibitor, elacridar (GF120918) as dual infusion in rats","display_name":"Optimization of dose and route of administration of the P\u2010glycoprotein inhibitor, valspodar (PSC\u2010833) and the P\u2010glycoprotein and breast cancer resistance protein dual\u2010inhibitor, elacridar (GF120918) as dual infusion in rats","publication_year":2021,"publication_date":"2021-03-04","ids":{"openalex":"https://openalex.org/W3133664844","doi":"https://doi.org/10.1002/prp2.740","mag":"3133664844","pmid":"https://pubmed.ncbi.nlm.nih.gov/33660938","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/7931226"},"language":"en","primary_location":{"id":"doi:10.1002/prp2.740","doi":"https://doi.org/10.1002/prp2.740","is_oa":true,"landing_page_url":"https://doi.org/10.1002/prp2.740","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/prp2.740","source":{"id":"https://openalex.org/S2764487716","display_name":"Pharmacology Research & Perspectives","issn_l":"2052-1707","issn":["2052-1707"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacology Research & Perspectives","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/prp2.740","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5079493001","display_name":"Christopher Rowbottom","orcid":"https://orcid.org/0000-0003-2492-3849","observed_orcids":["https://orcid.org/0000-0003-2492-3849"]},"institutions":[{"id":"https://openalex.org/I1297540436","display_name":"Biogen (United States)","ror":"https://ror.org/02jqkb192","country_code":"US","type":"company","lineage":["https://openalex.org/I1297540436"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Christopher Rowbottom","raw_affiliation_strings":["Biogen Inc, Cambridge, MA, USA"],"raw_orcid":"https://orcid.org/0000-0003-2492-3849","affiliations":[{"raw_affiliation_string":"Biogen Inc, Cambridge, MA, USA","institution_ids":["https://openalex.org/I1297540436"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005339359","display_name":"Alicia Pietrasiewicz","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1297540436","display_name":"Biogen (United States)","ror":"https://ror.org/02jqkb192","country_code":"US","type":"company","lineage":["https://openalex.org/I1297540436"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Alicia Pietrasiewicz","raw_affiliation_strings":["Biogen Inc, Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biogen Inc, Cambridge, MA, USA","institution_ids":["https://openalex.org/I1297540436"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087864660","display_name":"Taras Tuczewycz","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1297540436","display_name":"Biogen (United States)","ror":"https://ror.org/02jqkb192","country_code":"US","type":"company","lineage":["https://openalex.org/I1297540436"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Taras Tuczewycz","raw_affiliation_strings":["Biogen Inc, Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biogen Inc, Cambridge, MA, USA","institution_ids":["https://openalex.org/I1297540436"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017740261","display_name":"Richard Grater","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1297540436","display_name":"Biogen (United States)","ror":"https://ror.org/02jqkb192","country_code":"US","type":"company","lineage":["https://openalex.org/I1297540436"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Richard Grater","raw_affiliation_strings":["Biogen Inc, Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biogen Inc, Cambridge, MA, USA","institution_ids":["https://openalex.org/I1297540436"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5018006127","display_name":"Daniel Qiu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1297540436","display_name":"Biogen (United States)","ror":"https://ror.org/02jqkb192","country_code":"US","type":"company","lineage":["https://openalex.org/I1297540436"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel Qiu","raw_affiliation_strings":["Biogen Inc, Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biogen Inc, Cambridge, MA, USA","institution_ids":["https://openalex.org/I1297540436"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070822235","display_name":"Sudarshan Kapadnis","orcid":"https://orcid.org/0009-0001-2717-7442","observed_orcids":["https://orcid.org/0009-0001-2717-7442"]},"institutions":[{"id":"https://openalex.org/I1297540436","display_name":"Biogen (United States)","ror":"https://ror.org/02jqkb192","country_code":"US","type":"company","lineage":["https://openalex.org/I1297540436"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sudarshan Kapadnis","raw_affiliation_strings":["Biogen Inc, Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biogen Inc, Cambridge, MA, USA","institution_ids":["https://openalex.org/I1297540436"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5069822265","display_name":"Patrick E. Trapa","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1297540436","display_name":"Biogen (United States)","ror":"https://ror.org/02jqkb192","country_code":"US","type":"company","lineage":["https://openalex.org/I1297540436"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Patrick Trapa","raw_affiliation_strings":["Biogen Inc, Cambridge, MA, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Biogen Inc, Cambridge, MA, USA","institution_ids":["https://openalex.org/I1297540436"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5079493001"],"corresponding_institution_ids":["https://openalex.org/I1297540436"],"apc_list":{"value":2875,"currency":"USD","value_usd":2875},"apc_paid":{"value":2875,"currency":"USD","value_usd":2875},"fwci":1.0004,"has_fulltext":true,"cited_by_count":17,"citation_normalized_percentile":{"value":0.77224563,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":92,"max":98},"biblio":{"volume":"9","issue":"2","first_page":"e00740","last_page":"e00740"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11872","display_name":"Barrier Structure and Function Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2808","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/valspodar","display_name":"valspodar","score":0.9210000038146973},{"id":"https://openalex.org/keywords/elacridar","display_name":"elacridar","score":0.9610000252723694},{"id":"https://openalex.org/keywords/p-glycoprotein-inhibition","display_name":"P-glycoprotein inhibition","score":0.8109999895095825},{"id":"https://openalex.org/keywords/abcg2","display_name":"ABCG2","score":0.9240000247955322},{"id":"https://openalex.org/keywords/brain-penetration","display_name":"brain penetration","score":0.7879999876022339},{"id":"https://openalex.org/keywords/dose-optimization","display_name":"dose optimization","score":0.7599999904632568},{"id":"https://openalex.org/keywords/route-of-administration","display_name":"route of administration","score":0.8700000047683716},{"id":"https://openalex.org/keywords/drug-transporters","display_name":"drug transporters","score":0.6000000238418579},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.4390000104904175}],"concepts":[{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.7304152846336365},{"id":"https://openalex.org/C2778707650","wikidata":"https://www.wikidata.org/wiki/Q412902","display_name":"P-glycoprotein","level":4,"score":0.7239689826965332},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.5805426836013794},{"id":"https://openalex.org/C200082930","wikidata":"https://www.wikidata.org/wiki/Q22327148","display_name":"Efflux","level":2,"score":0.5781600475311279},{"id":"https://openalex.org/C512196","wikidata":"https://www.wikidata.org/wiki/Q4650095","display_name":"Abcg2","level":5,"score":0.558785080909729},{"id":"https://openalex.org/C149011108","wikidata":"https://www.wikidata.org/wiki/Q652985","display_name":"Transporter","level":3,"score":0.5163596868515015},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.43779581785202026},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.3547021746635437},{"id":"https://openalex.org/C133936738","wikidata":"https://www.wikidata.org/wiki/Q643839","display_name":"Multiple drug resistance","level":3,"score":0.25748950242996216},{"id":"https://openalex.org/C44312359","wikidata":"https://www.wikidata.org/wiki/Q286958","display_name":"ATP-binding cassette transporter","level":4,"score":0.22677430510520935},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.08748945593833923},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C501593827","wikidata":"https://www.wikidata.org/wiki/Q12187","display_name":"Antibiotics","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000070997","descriptor_name":"ATP Binding Cassette Transporter, Subfamily G, Member 2","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D000070997","descriptor_name":"ATP Binding Cassette Transporter, Subfamily G, Member 2","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D000166","descriptor_name":"Acridines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000166","descriptor_name":"Acridines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001812","descriptor_name":"Blood-Brain Barrier","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003524","descriptor_name":"Cyclosporins","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D003524","descriptor_name":"Cyclosporins","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D007262","descriptor_name":"Infusions, Intravenous","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008657","descriptor_name":"Metabolic Clearance Rate","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013045","descriptor_name":"Species Specificity","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020168","descriptor_name":"ATP Binding Cassette Transporter, Subfamily B, Member 1","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D020168","descriptor_name":"ATP Binding Cassette Transporter, Subfamily B, Member 1","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D044005","descriptor_name":"Tetrahydroisoquinolines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D044005","descriptor_name":"Tetrahydroisoquinolines","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D051381","descriptor_name":"Rats","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D065567","descriptor_name":"Absorption, Physiological","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":4,"locations":[{"id":"doi:10.1002/prp2.740","doi":"https://doi.org/10.1002/prp2.740","is_oa":true,"landing_page_url":"https://doi.org/10.1002/prp2.740","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/prp2.740","source":{"id":"https://openalex.org/S2764487716","display_name":"Pharmacology Research & Perspectives","issn_l":"2052-1707","issn":["2052-1707"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacology Research & Perspectives","raw_type":"journal-article"},{"id":"pmid:33660938","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/33660938","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacology research & perspectives","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:7931226","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7931226/","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacol Res Perspect","raw_type":"Text"},{"id":"pmh:oai:doaj.org/article:103f00bec9d940f988399c1ce77485f6","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/103f00bec9d940f988399c1ce77485f6","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Pharmacology Research & Perspectives, Vol 9, Iss 2, Pp n/a-n/a (2021)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.1002/prp2.740","doi":"https://doi.org/10.1002/prp2.740","is_oa":true,"landing_page_url":"https://doi.org/10.1002/prp2.740","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/prp2.740","source":{"id":"https://openalex.org/S2764487716","display_name":"Pharmacology Research & Perspectives","issn_l":"2052-1707","issn":["2052-1707"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-d","doyens","jufo-1","ki-jl-1","medline","norway-1","oarl","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacology Research & Perspectives","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W3133664844.pdf","grobid_xml":"https://content.openalex.org/works/W3133664844.grobid-xml"},"referenced_works_count":58,"referenced_works":["https://openalex.org/W1501777540","https://openalex.org/W1905469811","https://openalex.org/W1969753954","https://openalex.org/W1973091091","https://openalex.org/W1979637658","https://openalex.org/W1992296963","https://openalex.org/W1993396387","https://openalex.org/W1995632100","https://openalex.org/W2016575780","https://openalex.org/W2017543810","https://openalex.org/W2056449991","https://openalex.org/W2063873761","https://openalex.org/W2065669196","https://openalex.org/W2079197876","https://openalex.org/W2095624641","https://openalex.org/W2098994365","https://openalex.org/W2107085652","https://openalex.org/W2108982217","https://openalex.org/W2111834967","https://openalex.org/W2113409294","https://openalex.org/W2120079964","https://openalex.org/W2120624849","https://openalex.org/W2125157091","https://openalex.org/W2128705526","https://openalex.org/W2132110939","https://openalex.org/W2133154751","https://openalex.org/W2133475198","https://openalex.org/W2134756034","https://openalex.org/W2135164614","https://openalex.org/W2136685638","https://openalex.org/W2141017219","https://openalex.org/W2143316657","https://openalex.org/W2146818709","https://openalex.org/W2150256001","https://openalex.org/W2151990858","https://openalex.org/W2157188763","https://openalex.org/W2158838192","https://openalex.org/W2161518657","https://openalex.org/W2161708812","https://openalex.org/W2163095058","https://openalex.org/W2163869631","https://openalex.org/W2253346903","https://openalex.org/W2256951323","https://openalex.org/W2308538238","https://openalex.org/W2574428496","https://openalex.org/W2604547648","https://openalex.org/W2607767274","https://openalex.org/W2679581061","https://openalex.org/W2796073152","https://openalex.org/W2803472158","https://openalex.org/W2809392875","https://openalex.org/W2892317473","https://openalex.org/W2898747419","https://openalex.org/W2914730793","https://openalex.org/W2917680118","https://openalex.org/W2921868293","https://openalex.org/W4244859968","https://openalex.org/W4246081696"],"related_works":["https://openalex.org/W4390883873","https://openalex.org/W2781999975","https://openalex.org/W2143847158","https://openalex.org/W2111834967","https://openalex.org/W2049055032","https://openalex.org/W1964184604","https://openalex.org/W7100287211","https://openalex.org/W2145772015","https://openalex.org/W2755271241","https://openalex.org/W2044175162"],"abstract_inverted_index":{"Transporters":[0],"can":[1,222,238],"play":[2],"a":[3,61,68,111,132],"key":[4],"role":[5],"in":[6,19,39,187,200,207],"the":[7,28,35,48,54,80,107,119,138,142,152,158,184,211,220],"absorption,":[8,234],"distribution,":[9],"metabolism,":[10],"and":[11,56,67,86,110,147,171,180,216],"excretion":[12],"of":[13,27,37,47,58,60,113,134,140,145,151,194,228,244],"drugs.":[14],"Understanding":[15],"these":[16],"contributions":[17],"early":[18],"drug":[20],"discovery":[21],"allows":[22,203],"for":[23,95,204],"more":[24],"accurate":[25],"projection":[26],"clinical":[29],"pharmacokinetics.":[30],"One":[31],"method":[32],"to":[33,52,93,157,177,226,241],"assess":[34,137],"impact":[36,82],"transporters":[38,199,243],"vivo":[40],"involves":[41],"co-dosing":[42],"specific":[43],"inhibitors.":[44,248],"The":[45,100],"objective":[46],"present":[49],"study":[50],"was":[51,91,103,116,125],"optimize":[53],"dose":[55,98],"route":[57],"administration":[59],"P-glycoprotein":[62],"(P-gp)":[63],"inhibitor,":[64,75],"valspodar":[65,170],"(PSC833),":[66],"dual":[69],"P-gp/breast":[70],"cancer":[71],"resistance":[72],"protein":[73],"(BCRP)":[74],"elacridar":[76,124,174],"(GF120918),":[77],"by":[78,197],"assessing":[79],"transporters'":[81],"on":[83],"brain":[84,146],"penetration":[85],"absorption.":[87],"A":[88],"dual-infusion":[89],"strategy":[90],"implemented":[92],"allow":[94],"flexibility":[96],"with":[97],"formulation.":[99],"chemical":[101],"inhibitor":[102],"dosed":[104],"intravenously":[105],"via":[106,118],"femoral":[108],"artery,":[109],"cassette":[112],"known":[114,153],"substrates":[115,154],"infused":[117],"jugular":[120],"vein.":[121],"Valspodar":[122],"or":[123,237],"administered":[126],"as":[127],"4.5-hour":[128],"constant":[129],"infusions":[130],"over":[131],"range":[133],"doses.":[135],"To":[136],"degree":[139],"inhibition,":[141],"resulting":[143],"ratios":[144],"plasma":[148],"concentrations,":[149],"Kp's,":[150],"were":[155,175],"compared":[156],"vehicle":[159],"control.":[160],"These":[161],"data":[162],"demonstrated":[163],"that":[164],"doses":[165],"greater":[166],"than":[167],"0.9":[168],"mg/hr/kg":[169,173],"8.9":[172],"sufficient":[176],"inhibit":[178],"P-gp-":[179],"BCRP-mediated":[181],"efflux":[182,198,229],"at":[183,214,230],"blood-brain":[185],"barrier":[186],"rats":[188],"without":[189],"any":[190],"tolerability":[191],"issues.":[192],"Confirmation":[193],"BBB":[195],"restriction":[196],"preclinical":[201],"species":[202],"subsequent":[205],"prediction":[206],"humans":[208],"based":[209],"upon":[210],"proteomic":[212],"expression":[213],"rodent":[215],"human":[217],"BBB.":[218],"Overall,":[219],"approach":[221],"also":[223],"be":[224,239],"applied":[225],"inhibition":[227],"other":[231,242],"tissues":[232],"(gut":[233],"liver":[235],"clearance)":[236],"extended":[240],"interest":[245],"using":[246],"alternate":[247]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":6},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":2}],"updated_date":"2026-11-10T11:39:43.021295","created_date":"2021-03-15T00:00:00"}